These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6117304)

  • 21. Comment on the comment on nadolol article.
    Drug Intell Clin Pharm; 1981; 15(7-8):603. PubMed ID: 6113946
    [No Abstract]   [Full Text] [Related]  

  • 22. Nadolol and potassium iodide in combination in the surgical treatment of thyrotoxicosis.
    Peden NR; Gunn A; Browning MC; Crooks J; Forrest AL; Hamilton WF; Isles TE
    Br J Surg; 1982 Nov; 69(11):638-40. PubMed ID: 6127134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term treatment of essential hypertension with Nadolol and Hydrochlorothiazide: a two-year follow-up.
    El-Mehairy MM; Shaker A; Ramadan M; Hamza S; Tadros SS
    J Int Med Res; 1982; 10(2):87-91. PubMed ID: 6802691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. beta-2 Adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol.
    Hiatt WR; Wolfel EE; Stoll S; Nies AS; Zerbe GO; Brammell HL; Horwitz LD
    Clin Pharmacol Ther; 1985 Jan; 37(1):2-6. PubMed ID: 2856902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A study of nadolol to determine its effect on ambulatory blood pressure over 24 hours, and during exercise testing.
    Hornung RS; Gould BA; Kieso H; Raftery EB
    Br J Clin Pharmacol; 1982 Jul; 14(1):83-8. PubMed ID: 6125200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta adrenoceptor blockade and responses of serum lipids to a meal and to exercise.
    Peden NR; Dow RJ; Isles TE; Martin BT
    Br Med J (Clin Res Ed); 1984 Jun; 288(6433):1788-90. PubMed ID: 6145480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioequivalence of two tablet formulations of nadolol using single and multiple dose data: assessment using stereospecific and nonstereospecific assays.
    Srinivas NR; Barr WH; Shyu WC; Mohandoss E; Chow S; Staggers J; Balan G; Belas FJ; Blair IA; Barbhaiya RH
    J Pharm Sci; 1996 Mar; 85(3):299-303. PubMed ID: 8699333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minoxidil, nadolol, and a diuretic. Once-a-day therapy for resistant hypertension.
    Spitalewitz S; Porush JG; Reiser IW
    Arch Intern Med; 1986 May; 146(5):882-6. PubMed ID: 3963979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term treatment of essential hypertension using nadolol and hydrochlorothiazide combined.
    El-Mehairy MM; Shaker A; Ramadan M; Hamza S; Tadros SS
    Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):199S-203S. PubMed ID: 37875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nadolol antihypertensive effect and disposition in young and elderly adults with mild to moderate essential hypertension.
    Mitenko PA; McKenzie JK; Sitar DS; Penner SB; Aoki FY
    Clin Pharmacol Ther; 1989 Jul; 46(1):56-62. PubMed ID: 2663317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of serum nadolol levels by GLC--selected ion monitoring mass spectrometry: comparison with a spectrofluorometric method.
    Funke PT; Malley MF; Ivashkiv E; Cohen AI
    J Pharm Sci; 1978 May; 67(5):653-7. PubMed ID: 25332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial experience with a new long-acting beta-blocker, nadolol, in hypertensive patients.
    Hitzenberger G
    J Int Med Res; 1979; 7(1):33-8. PubMed ID: 33862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of the beta-blocker nadolol on the second messenger, serum cyclic adenosine monophosphate, and on blood pressure and heart rate].
    Weth G; Schneider J; Rodatz H; Haubitz I
    Arzneimittelforschung; 1985; 35(11):1711-3. PubMed ID: 2868733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.
    Heel RC; Brogden RN; Pakes GE; Speight TM; Avery GS
    Drugs; 1980 Jul; 20(1):1-23. PubMed ID: 6105067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Excretion of ibuprofen into breast milk.
    Townsend RJ; Benedetti TJ; Erickson SH; Cengiz C; Gillespie WR; Gschwend J; Albert KS
    Am J Obstet Gynecol; 1984 May; 149(2):184-6. PubMed ID: 6720796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial therapy of essential hypertension: diuretic or beta blocker?
    Finnerty FA
    J Fam Pract; 1980 Aug; 11(2):199-205. PubMed ID: 6106039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs in human milk. Clinical pharmacokinetic considerations.
    Atkinson HC; Begg EJ; Darlow BA
    Clin Pharmacokinet; 1988 Apr; 14(4):217-40. PubMed ID: 3292101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients.
    O'Callaghan WG; Laher MS; McGarry K; O'Brien E; O'Malley K
    Br J Clin Pharmacol; 1983 Oct; 16(4):417-21. PubMed ID: 6138058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absorption of the beta-adrenergic-blocking agent, nadolol, by mice, rats, hamsters, rabbits, dogs, monkeys, and man: an unusual species difference.
    Dreyfuss J; Shaw JM; Ross JJ
    Xenobiotica; 1978 Aug; 8(8):503-8. PubMed ID: 29379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.
    Wilcox RG; Hampton JR
    Br J Clin Pharmacol; 1982 Jun; 13(6):841-6. PubMed ID: 6124268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.